DK1928821T3 - Carboxamidderivater som muscarinreceptorantagonister - Google Patents

Carboxamidderivater som muscarinreceptorantagonister

Info

Publication number
DK1928821T3
DK1928821T3 DK06795581T DK06795581T DK1928821T3 DK 1928821 T3 DK1928821 T3 DK 1928821T3 DK 06795581 T DK06795581 T DK 06795581T DK 06795581 T DK06795581 T DK 06795581T DK 1928821 T3 DK1928821 T3 DK 1928821T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
muscarinic receptor
carboxamide derivatives
carboxamide
derivatives
Prior art date
Application number
DK06795581T
Other languages
English (en)
Inventor
Paul Alan Glossop
Simon John Mantell
Ross Sinclair Strang
Christine Anne Louise Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Application granted granted Critical
Publication of DK1928821T3 publication Critical patent/DK1928821T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK06795581T 2005-09-21 2006-09-01 Carboxamidderivater som muscarinreceptorantagonister DK1928821T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
DK1928821T3 true DK1928821T3 (da) 2009-03-16

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06795581T DK1928821T3 (da) 2005-09-21 2006-09-01 Carboxamidderivater som muscarinreceptorantagonister

Country Status (43)

Country Link
US (3) US7772223B2 (da)
EP (1) EP1928821B1 (da)
JP (1) JP4221447B1 (da)
KR (1) KR100976909B1 (da)
CN (1) CN101268046B (da)
AP (1) AP1983A (da)
AR (1) AR055171A1 (da)
AT (1) ATE420069T1 (da)
AU (1) AU2006293618B9 (da)
BR (1) BRPI0616111B8 (da)
CA (1) CA2623332C (da)
CR (2) CR9814A (da)
CU (1) CU20100115A7 (da)
CY (1) CY1108880T1 (da)
DE (1) DE602006004768D1 (da)
DK (1) DK1928821T3 (da)
DO (1) DOP2006000202A (da)
EA (1) EA013083B1 (da)
EC (1) ECSP088265A (da)
ES (1) ES2318794T3 (da)
GE (1) GEP20104880B (da)
GT (1) GT200600422A (da)
HK (1) HK1117163A1 (da)
HN (1) HN2006032615A (da)
HR (1) HRP20090127T3 (da)
IL (1) IL189453A (da)
MA (1) MA29839B1 (da)
ME (1) ME01106B (da)
MX (1) MX2008002805A (da)
MY (1) MY143581A (da)
NL (1) NL2000241C2 (da)
NO (1) NO340975B1 (da)
NZ (1) NZ566023A (da)
PE (1) PE20070460A1 (da)
PL (1) PL1928821T3 (da)
PT (1) PT1928821E (da)
RS (2) RS50855B (da)
SI (1) SI1928821T1 (da)
TN (1) TNSN08137A1 (da)
TW (1) TWI322143B (da)
UY (1) UY29798A1 (da)
WO (1) WO2007034325A1 (da)
ZA (1) ZA200801432B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
US20100160279A1 (en) * 2006-09-22 2010-06-24 Pfizer Inc Azetidine Derivatives as Muscarinic Receptor Antagonists
US8263583B2 (en) * 2007-03-16 2012-09-11 Pfizer Limited Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
EP2609065B1 (en) * 2010-08-26 2015-07-08 Albemarle Corporation Processes for producing 1-bromo-2 (cyclopropyl methoxy)-5 fluoro-4- methoxybenzene
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (en) * 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN114732910A (zh) 2017-10-05 2022-07-12 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69720518T2 (de) * 1996-12-02 2004-02-26 Kyorin Pharmaceutical Co., Ltd. Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
DE59611439D1 (de) * 1996-12-17 2007-09-06 Filtertek Bv Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
RU2005111589A (ru) 2002-09-17 2006-01-20 Актелион Фармасьютиклз Лтд. (Ch) Производные 1-пиридин-4-илмочевины

Also Published As

Publication number Publication date
ZA200801432B (en) 2009-07-29
RS51680B (en) 2011-10-31
RS50855B (sr) 2010-08-31
CN101268046B (zh) 2012-07-25
WO2007034325A1 (en) 2007-03-29
AU2006293618B9 (en) 2009-10-29
ME01106B (me) 2013-03-20
JP4221447B1 (ja) 2009-02-12
US7772223B2 (en) 2010-08-10
KR20080037103A (ko) 2008-04-29
NO20081001L (no) 2008-03-25
NL2000241C2 (nl) 2009-01-05
US8268881B2 (en) 2012-09-18
BRPI0616111B8 (pt) 2021-05-25
BRPI0616111A2 (pt) 2011-06-07
US20070105831A1 (en) 2007-05-10
CY1108880T1 (el) 2014-07-02
EA200800540A1 (ru) 2008-08-29
GEP20104880B (en) 2010-01-11
HK1117163A1 (en) 2009-01-09
GT200600422A (es) 2007-05-28
PL1928821T3 (pl) 2009-06-30
CR9814A (es) 2008-04-16
CA2623332C (en) 2012-05-01
IL189453A (en) 2014-06-30
PT1928821E (pt) 2009-03-10
CN101268046A (zh) 2008-09-17
DE602006004768D1 (de) 2009-02-26
ECSP088265A (es) 2008-04-28
ES2318794T3 (es) 2009-05-01
AR055171A1 (es) 2007-08-08
RS20080119A (en) 2009-05-06
JP2009508933A (ja) 2009-03-05
US20100029720A1 (en) 2010-02-04
NL2000241A1 (nl) 2007-03-22
TNSN08137A1 (fr) 2009-07-14
SI1928821T1 (sl) 2009-04-30
AP1983A (en) 2009-03-24
CU23910B1 (da) 2013-06-29
US20110251164A1 (en) 2011-10-13
US8486992B2 (en) 2013-07-16
TW200745024A (en) 2007-12-16
CU20100115A7 (es) 2011-10-14
NZ566023A (en) 2010-02-26
AU2006293618B2 (en) 2009-10-08
HN2006032615A (es) 2010-10-04
MY143581A (en) 2011-05-31
NO340975B1 (no) 2017-07-31
IL189453A0 (en) 2008-08-07
CR20130209A (es) 2013-09-19
TWI322143B (en) 2010-03-21
MA29839B1 (fr) 2008-10-03
EA013083B1 (ru) 2010-02-26
AU2006293618A1 (en) 2007-03-29
PE20070460A1 (es) 2007-05-14
DOP2006000202A (es) 2007-04-15
EP1928821A1 (en) 2008-06-11
CA2623332A1 (en) 2007-03-29
EP1928821B1 (en) 2009-01-07
UY29798A1 (es) 2007-04-30
MX2008002805A (es) 2008-04-07
KR100976909B1 (ko) 2010-08-18
BRPI0616111B1 (pt) 2019-10-08
HRP20090127T3 (en) 2009-06-30
ATE420069T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DK1928821T3 (da) Carboxamidderivater som muscarinreceptorantagonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DK2094690T3 (da) 2-aza-bicyclo[3.1.0]hexanderivater som orexinreceptorantagonister
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DK1951660T3 (da) Histamin-3-receptorantagonister
DK1856042T3 (da) Substituerede gamma-lactamer som terapeutiske midler
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1723114T3 (da) Biphenyl-forbindelser der er egnede som muskarinreceptorantagonister
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DK2170831T3 (da) Benzazepin-derivater egnede som vasopressin-antagonister
DK2089367T3 (da) Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
IL192308A0 (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
DK1912976T3 (da) Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister